Literature DB >> 21668318

Leydig cell tumour of the ovary localised with positron emission tomography/computed tomography.

Vasileios Prassopoulos1, Fotios Laspas, Fani Vlachou, Roxani Efthimiadou, Lida Gogou, John Andreou.   

Abstract

Androgen-producing ovarian tumours can lead to assessment difficulties because of their small size. We present a case of virilising steroid cell ovarian tumour in a 41-year-old woman localised with Fluorine-18-Deoxyglucose Positron Emission Tomography/Computed Tomography ((18)FDG-PET/CT). Although the biochemical evaluation pointed to an ovarian source of androgen, diagnostic attempts to localise the source of hyperandrogenism with transvaginal ultrasound (US), and magnetic resonance imaging (MRI) of pelvis failed. Additional evaluation with (18)FDG-PET/CT showed an increased uptake in the right ovary. A laparoscopic right oophorectomy was performed and histopathology examination revealed a 1.2-cm Leydig cell tumour. The patient showed regression of clinical signs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668318     DOI: 10.3109/09513590.2010.521263

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  4 in total

1.  Leydig cell tumor incidentally detected by fused FDG-PET/MRI.

Authors:  Giorgio Treglia; Vittoria Espeli; Luca Giovanella
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

2.  Total testosterone levels are often more than three times elevated in patients with androgen-secreting tumours.

Authors:  Dorte Glintborg; Magda L Altinok; Kresten R Petersen; Pernille Ravn
Journal:  BMJ Case Rep       Date:  2015-01-23

3.  "Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging.

Authors:  Rosa Maria Paragliola; Francesco Torino; Paola Senes; Laura Castellino; Vanda Salutari; Alfredo Pontecorvi; Giovanni Scambia; Salvatore M Corsello
Journal:  Endocrine       Date:  2013-10-04       Impact factor: 3.633

4.  Occult leydig cell tumour and androgen-receptor positive breast cancer in a woman with severe hyperandrogenism.

Authors:  Giovanna Saraceno; Valeria Barresi; Francesco Trimarchi; Salvatore Cannavo
Journal:  J Ovarian Res       Date:  2013-07-01       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.